Sage Therapeutics Inc. (NASDAQ:SAGE) Relative Strength Index (RSI) is 48.30, with weekly volatility at 5.19% and ATR at 4.38. The SAGE stock’s 52-week price range has touched low of $25.01 and a $98.39 high. Intraday shares traded counted 0.47 million, which was 28.09% higher than its 30-day average trading volume of 654.67K. Its shares traded higher over the last trading session, gaining 4.92% on 02/19/21. The shares fell to a low of $79.42 before closing at $82.33. SAGE’s previous close was $78.47 while the outstanding shares total 51.98M. The firm has a beta of 1.99.
Investors have identified the Biotechnology company Sage Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $4.57 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Sage Therapeutics Inc. (SAGE) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 698.88 million total, with 59.66 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -4.11 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SAGE sounds very interesting.
Is the stock of SAGE attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
14 out of 22 analysts covering the stock have rated it a Buy, while 8 have maintained a Hold recommendation on Sage Therapeutics Inc.. 0 analysts has assigned a Sell rating on the SAGE stock. The 12-month mean consensus price target for the company’s shares has been set at $99.20.